Krilogy Financial LLC Acquires 2,421 Shares of Johnson & Johnson $JNJ

Key Points

• Krilogy Financial LLC increased its stake in Johnson & Johnson by 20.4% during Q2, owning a total of 14,314 shares valued at approximately $2.2 million.
• Johnson & Johnson reported earnings of $2.77 per share for the last quarter, exceeding expectations and achieving a year-over-year revenue increase of 5.8% to $23.74 billion.
• The company recently declared a quarterly dividend of $1.30 per share, equating to an annualized dividend of $5.20 and a yield of 2.9%.

Krilogy Financial LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 20.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 14,314 shares of the company's stock after purchasing an additional 2,421 shares during the quarter. Krilogy Financial LLC's holdings in Johnson & Johnson were worth $2,186,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Nuveen LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth about $1,369,188,000. GAMMA Investing LLC increased its stake in Johnson & Johnson by 24,450.4% during the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock valued at $1,196,596,000 after purchasing an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after buying an additional 4,842,582 shares during the last quarter. Pacer Advisors Inc. lifted its stake in shares of Johnson & Johnson by 1,382.0% in the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock worth $502,509,000 after buying an additional 2,825,626 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $349,206,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.5%

Shares of JNJ stock opened at $176.48 on Wednesday. The company has a market cap of $425.02 billion, a PE ratio of 18.87, a price-to-earnings-growth ratio of 2.26 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock's 50 day simple moving average is $171.67 and its two-hundred day simple moving average is $161.46. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the prior year, the firm posted $2.82 earnings per share. The business's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's payout ratio is presently 55.61%.

Analysts Set New Price Targets

JNJ has been the subject of several recent analyst reports. Morgan Stanley boosted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. UBS Group boosted their target price on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Bank of America raised their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Finally, Barclays increased their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $176.29.

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.